請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68879
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林慧玲(Fe-Lin Lin Wu),胡瑞恒(Rey-Heng Hu),蔡孟昆(Meng-Kun Tsai) | |
dc.contributor.author | Yi-Ming Huang | en |
dc.contributor.author | 黃義茗 | zh_TW |
dc.date.accessioned | 2021-06-17T02:40:00Z | - |
dc.date.available | 2022-09-14 | |
dc.date.copyright | 2017-09-14 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-08-16 | |
dc.identifier.citation | 1. Martin P, DiMartini A, Feng S, Brown R, Jr., Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology (Baltimore, Md) 2014;59:1144-65.
2. Neuberger J. An update on liver transplantation: A critical review. Journal of autoimmunity 2016;66:51-9. 3. Huang YY, Hsu CC, Chou CL, Loong CC, Wu MS, Chou YC. Trends in the use of maintenance immunosuppressive drugs among liver transplant recipients in Taiwan: a nationwide population-based study. Pharmacoepidemiology and drug safety 2016;25:661-7. 4. Malvezzi P, Rostaing L. The safety of calcineurin inhibitors for kidney-transplant patients. Expert opinion on drug safety 2015;14:1531-46. 5. Vicari-Christensen M, Repper S, Basile S, Young D. Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners' understanding and offer strategies for educating patients and promoting adherence. Progress in transplantation (Aliso Viejo, Calif) 2009;19:277-84. 6. Herzer K, Strassburg CP, Braun F, et al. Selection and use of immunosuppressive therapies after liver transplantation: current German practice. Clinical transplantation 2016;30:487-501. 7. Rodriguez-Peralvarez M, Germani G, Darius T, Lerut J, Tsochatzis E, Burroughs AK. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2012;12:2797-814. 8. Rodriguez-Peralvarez M, Germani G, Papastergiou V, et al. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome. Journal of hepatology 2013;58:262-70. 9. Barbarino JM, Staatz CE, Venkataramanan R, Klein TE, Altman RB. PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenetics and genomics 2013;23:563-85. 10. Moini M, Schilsky ML, Tichy EM. Review on immunosuppression in liver transplantation. World Journal of Hepatology 2015;7:1355-68. 11. Ban YH, Park SR, Yoon YJ. The biosynthetic pathway of FK506 and its engineering: from past achievements to future prospects. Journal of industrial microbiology & biotechnology 2016;43:389-400. 12. Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplantation proceedings 2004;36:25s-32s. 13. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clinical pharmacokinetics 2004;43:623-53. 14. Posadas Salas MA, Srinivas TR. Update on the clinical utility of once-daily tacrolimus in the management of transplantation. Drug design, development and therapy 2014;8:1183-94. 15. Shuker N, van Gelder T, Hesselink DA. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management. Transplantation reviews (Orlando, Fla) 2015;29:78-84. 16. Liu JO. Calmodulin-dependent phosphatase, kinases, and transcriptional corepressors involved in T-cell activation. Immunological reviews 2009;228:184-98. 17. Hesselink DA, Bouamar R, Elens L, van Schaik RH, van Gelder T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clinical pharmacokinetics 2014;53:123-39. 18. Choudhary NS, Saigal S, Shukla R, Kotecha H, Saraf N, Soin AS. Current Status of Immunosuppression in Liver Transplantation. Journal of Clinical and Experimental Hepatology 2013;3:150-8. 19. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clinical journal of the American Society of Nephrology : CJASN 2009;4:481-508. 20. Yates CJ, Fourlanos S, Hjelmesaeth J, Colman PG, Cohney SJ. New-onset diabetes after kidney transplantation-changes and challenges. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2012;12:820-8. 21. First MR. First clinical experience with the new once-daily formulation of tacrolimus. Therapeutic drug monitoring 2008;30:159-66. 22. Tanzi MG, Undre N, Keirns J, Fitzsimmons WE, Brown M, First MR. Pharmacokinetics of prolonged-release tacrolimus and implications for use in solid organ transplant recipients. Clinical transplantation 2016;30:901-11. 23. Barraclough KA, Isbel NM, Johnson DW, Campbell SB, Staatz CE. Once- versus twice-daily tacrolimus: are the formulations truly equivalent? Drugs 2011;71:1561-77. 24. van Gelder T. Drug interactions with tacrolimus. Drug safety 2002;25:707-12. 25. Patel N, Cook A, Greenhalgh E, Rech MA, Rusinak J, Heinrich L. Overview of extended release tacrolimus in solid organ transplantation. World journal of transplantation 2016;6:144-54. 26. Wijnen RM, Ericzon BG, Tiebosch AT, Beysens AJ, Groth CG, Kootstra G. Toxicity of FK 506 in the cynomolgus monkey: noncorrelation with FK 506 serum levels. Transplantation proceedings 1991;23:3101-4. 27. Vanhove T, Annaert P, Kuypers DR. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug metabolism reviews 2016;48:88-112. 28. Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug metabolism and pharmacokinetics 2007;22:328-35. 29. Knops N, Levtchenko E, van den Heuvel B, Kuypers D. From gut to kidney: transporting and metabolizing calcineurin-inhibitors in solid organ transplantation. International journal of pharmaceutics 2013;452:14-35. 30. Kiuchi T, Kasahara M, Uryuhara K, et al. Impact of graft size mismatching on graft prognosis in liver transplantation from living donors. Transplantation 1999;67:321-7. 31. Haga J, Shimazu M, Wakabayashi G, et al. Liver regeneration in donors and adult recipients after living donor liver transplantation. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2008;14:1718-24. 32. Andrews LM, Riva N, de Winter BC, et al. Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients. Expert opinion on drug metabolism & toxicology 2015;11:921-36. 33. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature genetics 2001;27:383-91. 34. Provenzani A, Notarbartolo M, Labbozzetta M, et al. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. International journal of molecular medicine 2011;28:1093-102. 35. Argudo A, Gonzalez de Aledo JM, Alia P, et al. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation. Transplantation proceedings 2015;47:2388-92. 36. Gerard C, Stocco J, Hulin A, et al. Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach. The AAPS journal 2014;16:379-91. 37. Chen D, Guo F, Shi J, et al. Association of hemoglobin levels, CYP3A5, and NR1I3 gene polymorphisms with tacrolimus pharmacokinetics in liver transplant patients. Drug metabolism and pharmacokinetics 2014;29:249-53. 38. Rojas LE, Herrero MJ, Boso V, et al. Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation. Pharmacogenetics and genomics 2013;23:509-17. 39. Tang HL, Xie HG, Yao Y, Hu YF. Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. Pharmacogenetics and genomics 2011;21:713-20. 40. Uesugi M, Kikuchi M, Shinke H, et al. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation. Pharmacogenetics and genomics 2014;24:356-66. 41. Kato H, Usui M, Muraki Y, et al. Long-Term Influence of CYP3A5 Gene Polymorphism on Pharmacokinetics of Tacrolimus and Patient Outcome After Living Donor Liver Transplantation. Transplantation proceedings 2016;48:1087-94. 42. Wang L, Liu LH, Tong WH, Wang MX, Lu SC. Effect of CYP3A5 gene polymorphisms on tacrolimus concentration/dosage ratio in adult liver transplant patients. Genetics and molecular research : GMR 2015;14:15148-57. 43. Ji E, Choi L, Suh KS, Cho JY, Han N, Oh JM. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. Transplantation 2012;94:866-72. 44. Buendia JA, Bramuglia G, Staatz CE. Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis. Therapeutic drug monitoring 2014;36:442-7. 45. Gomez-Bravo MA, Salcedo M, Fondevila C, et al. Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients. Journal of clinical pharmacology 2013;53:1146-54. 46. Muraki Y, Usui M, Isaji S, et al. Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients. Annals of transplantation 2011;16:55-62. 47. Zuo XC, Ng CM, Barrett JS, et al. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenetics and genomics 2013;23:251-61. 48. Li CJ, Li L, Lin L, et al. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients. PloS one 2014;9:e86206. 49. Uesugi M, Hosokawa M, Shinke H, et al. Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients. Biological & pharmaceutical bulletin 2013;36:1814-21. 50. Shi XJ, Geng F, Jiao Z, Cui XY, Qiu XY, Zhong MK. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis. Journal of clinical pharmacy and therapeutics 2011;36:614-24. 51. Li DY, Teng RC, Zhu HJ, Fang Y. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients. International journal of clinical pharmacology and therapeutics 2013;51:466-74. 52. Jun KR, Lee W, Jang MS, et al. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. Transplantation 2009;87:1225-31. 53. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clinical pharmacokinetics 2010;49:141-75. 54. Provenzani A, Santeusanio A, Mathis E, et al. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World journal of gastroenterology 2013;19:9156-73. 55. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proceedings of the National Academy of Sciences of the United States of America 1987;84:7735-8. 56. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clinical pharmacokinetics 2003;42:59-98. 57. Li D, Zhu JY, Gao J, Wang X, Lou YQ, Zhang GL. Polymorphisms of tumor necrosis factor-alpha, interleukin-10, cytochrome P450 3A5 and ABCB1 in Chinese liver transplant patients treated with immunosuppressant tacrolimus. Clinica chimica acta; international journal of clinical chemistry 2007;383:133-9. 58. Wei-lin W, Jing J, Shu-sen Z, et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2006;12:775-80. 59. Liu YY, Li C, Cui Z, et al. The effect of ABCB1 C3435T polymorphism on pharmacokinetics of tacrolimus in liver transplantation: a meta-analysis. Gene 2013;531:476-88. 60. Elens L, Sombogaard F, Hesselink DA, van Schaik RH, van Gelder T. Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-alpha are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus. Pharmacogenetics and genomics 2013;23:649-57. 61. Elens L, Nieuweboer AJ, Clarke SJ, et al. Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenetics and genomics 2013;23:148-55. 62. de Jonge H, Metalidis C, Naesens M, Lambrechts D, Kuypers DR. The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics 2011;12:1281-91. 63. Jannot AS, Vuillemin X, Etienne I, et al. A Lack of Significant Effect of POR*28 Allelic Variant on Tacrolimus Exposure in Kidney Transplant Recipients. Therapeutic drug monitoring 2016;38:223-9. 64. 張書榕. ABCB1、CYP3A4、CYP3A5、POR基因多型性及其他因素對腎臟與肝臟移植病人tacrolimus血中濃度之影響. 2016. 65. Tacrolimus. Drugdex Informaction System. Micromedex; 2016. 66. ABBOTT ARCHITECT Tacrolimus package insert. 2009. 67. Kim IW, Moon YJ, Ji E, et al. Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients. European journal of clinical pharmacology 2012;68:657-69. 68. Coilly A, Calmus Y, Chermak F, et al. Once-daily prolonged release tacrolimus in liver transplantation: Experts' literature review and recommendations. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2015;21:1312-21. 69. Staatz CE, Tett SE. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients. Clinical pharmacokinetics 2015;54:993-1025. 70. Fischer L, Trunecka P, Gridelli B, et al. Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2011;17:167-77. 71. Zhu L, Yang J, Zhang Y, Jing Y, Zhang Y, Li G. Effects of CYP3A5 genotypes, ABCB1 C3435T and G2677T/A polymorphism on pharmacokinetics of Tacrolimus in Chinese adult liver transplant patients. Xenobiotica; the fate of foreign compounds in biological systems 2015;45:840-6. 72. Antignac M, Hulot JS, Boleslawski E, et al. Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. European journal of clinical pharmacology 2005;61:409-16. 73. Oteo I, Lukas JC, Leal N, et al. Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction. European journal of clinical pharmacology 2013;69:65-74. 74. Kanaan N PC, Hassoun Z et al. Does Infection Impact On Tacrolimus Blood Levels in Kidney Transplant Recipients? American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2015;15 Suppl 3:S1. 75. Nakamura A, Amada N, Haga I, Tokodai K, Kashiwadate T. Effects of elevated tacrolimus trough levels in association with infectious enteritis on graft function in renal transplant recipients. Transplantation proceedings 2014;46:592-4. 76. Peloso LJ, Faria PN, Bossolani MV, de Oliveira HB, Ferreira Filho SR. The serum concentration of tacrolimus after ingesting omeprazole: a pilot study. Transplantation 2014;98:e63-4. 77. Itagaki F, Homma M, Yuzawa K, et al. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. The Journal of pharmacy and pharmacology 2004;56:1055-9. 78. Hosohata K, Masuda S, Yonezawa A, et al. Absence of influence of concomitant administration of rabeprazole on the pharmacokinetics of tacrolimus in adult living-donor liver transplant patients: a case-control study. Drug metabolism and pharmacokinetics 2009;24:458-63. 79. Isoda K, Takeuchi T, Kotani T, et al. The proton pump inhibitor lansoprazole, but not rabeprazole, the increased blood concentrations of calcineurin inhibitors in Japanese patients with connective tissue diseases. Intern Med 2014;53:1413-8. 80. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole. Aliment Pharmacol Ther 1999;13 Suppl 3:27-36. 81. Hosohata K, Masuda S, Ogura Y, et al. Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. Drug metabolism and pharmacokinetics 2008;23:134-8. 82. Lorf T, Ramadori G, Ringe B, Schworer H. The effect of pantoprazole on tacrolimus and cyclosporin A blood concentration in transplant recipients. European journal of clinical pharmacology 2000;56:439-40. 83. Fan J, Zhang X, Ren L, et al. Donor IL-18 rs5744247 polymorphism as a new biomarker of tacrolimus elimination in Chinese liver transplant patients during the early post-transplantation period: results from two cohort studies. Pharmacogenomics 2015;16:239-50. 84. Lee JY, Hahn HJ, Son IJ, et al. Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients. Pharmacotherapy 2006;26:1069-77. 85. Taber DJ, Dupuis RE, Fann AL, et al. Tacrolimus dosing requirements and concentrations in adult living donor liver transplant recipients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2002;8:219-23. 86. Trotter JF, Stolpman N, Wachs M, et al. Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2002;8:212-8. 87. Almazroo OA, Miah MK, Venkataramanan R. Drug Metabolism in the Liver. Clinics in liver disease 2017;21:1-20. 88. Uesugi M, Masuda S, Katsura T, Oike F, Takada Y, Inui K. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenetics and genomics 2006;16:119-27. 89. Birdwell KA, Decker B, Barbarino JM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clinical pharmacology and therapeutics 2015;98:19-24. 90. Sherry ST WM, Kholodov M et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001;29(1):308-11. 91. Hu YF, Tu JH, Tan ZR, et al. Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica; the fate of foreign compounds in biological systems 2007;37:315-27. 92. Gao Y, Zhang LR, Fu Q. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. European journal of clinical pharmacology 2008;64:877-82. 93. Chen WY, Lee CY, Lin PY, et al. Betel Nut Chewing Is Associated With Reduced Tacrolimus Concentration in Taiwanese Liver Transplant Recipients. Transplantation proceedings 2017;49:326-9. 94. Ren L, Teng M, Zhang T, et al. Donors FMO3 polymorphisms affect tacrolimus elimination in Chinese liver transplant patients. Pharmacogenomics 2017;18:265-75. 95. Wang Z, Wu S, Chen D, et al. Influence of TLR4 rs1927907 locus polymorphisms on tacrolimus pharmacokinetics in the early stage after liver transplantation. European journal of clinical pharmacology 2014;70:925-31. 96. Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995;23:1315-24. 97. Christians U, Schmidt G, Bader A, et al. Identification of drugs inhibiting the in vitro metabolism of tacrolimus by human liver microsomes. British journal of clinical pharmacology 1996;41:187-90. 98. Ibrahim RB, Abella EM, Chandrasekar PH. Tacrolimus-clarithromycin interaction in a patient receiving bone marrow transplantation. The Annals of pharmacotherapy 2002;36:1971-2. 99. Wolter K, Wagner K, Philipp T, Fritschka E. Interaction between FK 506 and clarithromycin in a renal transplant patient. European journal of clinical pharmacology 1994;47:207-8. 100. Furlan V, Perello L, Jacquemin E, Debray D, Taburet AM. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. Transplantation 1995;59:1217-8. 101. Shaeffer MS, Collier D, Sorrell MF. Interaction between FK506 and erythromycin. The Annals of pharmacotherapy 1994;28:280-1. 102. Iwasaki K, Matsuda H, Nagase K, Shiraga T, Tokuma Y, Uchida K. Effects of twenty-three drugs on the metabolism of FK506 by human liver microsomes. Res Commun Chem Pathol Pharmacol 1993;82:209-16. 103. Matsuda H, Iwasaki K, Shiraga T, Tozuka Z, Hata T, Guengerich FP. Interactions of FK506 (tacrolimus) with clinically important drugs. Res Commun Mol Pathol Pharmacol 1996;91:57-64. 104. Prasad TN, Stiff DD, Subbotina N, et al. FK 506 (Tacrolimus) metabolism by rat liver microsomes and its inhibition by other drugs. Res Commun Chem Pathol Pharmacol 1994;84:35-46. 105. Mieles L, Venkataramanan R, Yokoyama I, Warty VJ, Starzl TE. Interaction between FK506 and clotrimazole in a liver transplant recipient. Transplantation 1991;52:1086-7. 106. Herzig K, Johnson DW. Marked elevation of blood cyclosporin and tacrolimus levels due to concurrent metronidazole therapy. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1999;14:521-3. 107. Page RL, 2nd, Klem PM, Rogers C. Potential elevation of tacrolimus trough concentrations with concomitant metronidazole therapy. The Annals of pharmacotherapy 2005;39:1109-13. 108. Roedler R, Neuhauser MM, Penzak SR. Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered? The Annals of pharmacotherapy 2007;41:653-8. 109. Assan R, Fredj G, Larger E, Feutren G, Bismuth H. FK 506/fluconazole interaction enhances FK 506 nephrotoxicity. Diabete Metab 1994;20:49-52. 110. Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996;61:1268-72. 111. Toda F, Tanabe K, Ito S, et al. Tacrolimus trough level adjustment after administration of fluconazole to kidney recipients. Transplant Proc 2002;34:1733-5. 112. Capone D, Gentile A, Imperatore P, Palmiero G, Basile V. Effects of itraconazole on tacrolimus blood concentrations in a renal transplant recipient. The Annals of pharmacotherapy 1999;33:1124-5. 113. Furlan V, Parquin F, Penaud JF, et al. Interaction between tacrolimus and itraconazole in a heart-lung transplant recipient. Transplant Proc 1998;30:187-8. 114. Floren LC, Bekersky I, Benet LZ, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clinical pharmacology and therapeutics 1997;62:41-9. 115. Tuteja S, Alloway RR, Johnson JA, Gaber AO. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 2001;71:1303-7. 116. Pai MP, Allen S. Voriconazole inhibition of tacrolimus metabolism. Clin Infect Dis 2003;36:1089-91. 117. Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002;46:3091-3. 118. Berge M, Chevalier P, Benammar M, et al. Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis. Therapeutic drug monitoring 2009;31:396-9. 119. De Lima JJ, Xue H, Coburn L, et al. Effects of FK506 in rat and human resistance arteries. Kidney Int 1999;55:1518-27. 120. Homma M, Itagaki F, Yuzawa K, Fukao K, Kohda Y. Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. Transplantation 2002;73:303-4. 121. Itagaki F, Homma M, Yuzawa K, Fukao K, Kohda Y. Drug interaction of tacrolimus and proton pump inhibitors in renal transplant recipients with CYP2C19 gene mutation. Transplant Proc 2002;34:2777-8. 122. Furuta S, Kamada E, Suzuki T, et al. Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica 2001;31:1-10. 123. Regazzi MB, Iacona I, Alessiani M, et al. Interaction between FK 506 and diltiazem in an animal model. Transplant Proc 1996;28:1017-8. 124. Tada H, Yanagiwara S, Ito K, Suzuki T. Role of diltiazem on tacrolimus pharmacokinetics in tacrolimus-induced nephrotoxic rats. Pharmacol Toxicol 1999;84:241-6. 125. Hebert MF, Lam AY. Diltiazem increases tacrolimus concentrations. The Annals of pharmacotherapy 1999;33:680-2. 126. Hooper DK, Fukuda T, Gardiner R, et al. Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. Transplantation 2012;93:806-12. 127. Hurst AL, Clark N, Carpenter TC, Sundaram SS, Reiter PD. Supra-therapeutic tacrolimus concentrations associated with concomitant nicardipine in pediatric liver transplant recipients. Pediatric transplantation 2015;19:E83-7. 128. Olyaei AJ, deMattos AM, Norman DJ, Bennett WM. Interaction between tacrolimus and nefazodone in a stable renal transplant recipient. Pharmacotherapy 1998;18:1356-9. 129. Boubenider S, Vincent I, Lambotte O, et al. Interaction between theophylline and tacrolimus in a renal transplant patient. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2000;15:1066-8. 130. Sheikh AM, Wolf DC, Lebovics E, Goldberg R, Horowitz HW. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation 1999;68:307-9. 131. Schvarcz R, Rudbeck G, Soderdahl G, Stahle L. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). Transplantation 2000;69:2194-5. 132. Jain AK, Venkataramanan R, Shapiro R, et al. Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients. Transplant Proc 2002;34:1540-1. 133. van de Plas A, Dackus J, Christiaans MH, Stolk LM, van Hooff JP, Neef C. A pilot study on sublingual administration of tacrolimus. Transplant international : official journal of the European Society for Organ Transplantation 2009;22:358-9. 134. Seifeldin RA, Marcos-Alvarez A, Gordon FD, Lewis WD, Jenkins RL. Nifedipine interaction with tacrolimus in liver transplant recipients. The Annals of pharmacotherapy 1997;31:571-5. 135. Zuo XC, Zhou YN, Zhang BK, et al. Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine. Drug metabolism and pharmacokinetics 2013;28:398-405. 136. Zhao W, Baudouin V, Fakhoury M, Storme T, Deschenes G, Jacqz-Aigrain E. Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child. Transplantation 2012;93:e29-30. 137. Mathis AS, Shah N, Knipp GT, Friedman GS. Interaction of chloramphenicol and the calcineurin inhibitors in renal transplant recipients. Transpl Infect Dis 2002;4:169-74. 138. Schulman SL, Shaw LM, Jabs K, Leonard MB, Brayman KL. Interaction between tacrolimus and chloramphenicol in a renal transplant recipient. Transplantation 1998;65:1397-8. 139. Mignat C. Clinically significant drug interactions with new immunosuppressive agents. Drug safety 1997;16:267-78. 140. Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Therapeutic drug monitoring 2007;29:687-710. 141. Finch CK, Chrisman CR, Baciewicz AM, Self TH. Rifampin and rifabutin drug interactions: an update. Arch Intern Med 2002;162:985-92. 142. Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999;39:91-6. 143. Kiuchi T, Tanaka K, Inomata Y, et al. Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. Transplant Proc 1996;28:3171-2. 144. Chenhsu RY, Loong CC, Chou MH, Lin MF, Yang WC. Renal allograft dysfunction associated with rifampin-tacrolimus interaction. The Annals of pharmacotherapy 2000;34:27-31. 145. Bhaloo S, Prasad GV. Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report. Transplant Proc 2003;35:2449-51. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68879 | - |
dc.description.abstract | 研究背景與目的:
臨床上發現肝臟移植病人,即使服用相同劑量的tacrolimus(TAC),個體間及個體內的血中谷濃度差異還是很大。在過去有許多研究發現不同因素會影響TAC的藥動學或血中濃度,但在台灣肝臟移植病人,尚未有研究不同因素及基因對TAC的影響,也沒有合併臨床因素及基因的研究,故本研究將所有可能影響TAC藥動學或血中濃度的臨床與基因因素納入分析,探討台灣肝臟移植病人各種因素及基因對於TAC劑量校正谷濃度的影響。 方法: 本研究分兩步驟分析:首先為受贈者臨床因素分析,再來為合併受贈者臨床因素與基因多型性的分析。病人納入條件包含在2008年1月1日至2015年7月31日肝臟移植的病人,並且在移植後使用TAC作為免疫抑制劑且須持續服用至少6個月,有檢測特定基因多型性,此外移植時的年齡須介於20到 65歲;排除條件包含再移植或多重器官移植、非亞裔以及人類免疫缺乏病毒反應呈陽性的病人;經過篩選後的病人,在回門診期間,自願提供檢體做基因檢測者則納入本試驗分析。TAC用劑量校正谷濃度(dose normalized trough concentrations,dnC0;與dosing weight and dose normalized trough concentrations,dnC0/DW)來表示,使用三個評估點:移植手術住院期間、移植後3個月以及移植後6個月。統計方法使用單變項分析因素及基因,當其p值<0.2則放入多元迴歸分析,並用逐步選取法找出顯著影響(p<0.05)TAC劑量校正血中濃度的因素,其他統計方法包含獨立樣本t檢定、ANOVA(analysis of variance)、Chi-squared test以及Fisher's exact test。 結果: 本研究納入123個肝臟移植病人,首先分析臨床因素,移植手術住院期間的多元迴歸分析,發現會顯著影響TAC dnC0或dnC0/DW的因素有TAC的劑型(Prograf ®或Advagraf ®)、direct bilirubin值、活體或屍體肝臟器官移植、PPI之使用以及hematocrit(Hct)值。在移植後3個月的多元迴歸分析,發現會顯著影響TAC dnC0或dnC0/DW的因素有Hemoglobin(Hb)、AST(aspartate aminotransferase)、TAC的劑型(Prograf ®或Advagraf ®)、感染以及BUN值。在移植後6個月的多元迴歸分析,發現會顯著影響TAC dnC0或dnC0/DW的因素有AST、total bilirubinu以及Hb。這些因素的個別解釋力範圍落在3-14%之間。 接者合併受贈者臨床因素及基因多型性分析,發現在移植後的三個評估點,一致顯示會顯著影響TAC dnC0與dnC0/DW的基因是CYP3A5*3,解釋力位於8-13%之間。將病人分成CYP3A5表現型和CYP3A5非表現型,CYP3A5非表現型的TAC dnC0與dnC0/DW是CYP3A5表現型的1.5至1.8倍。將病人分成CYP3A5*1/*1、CYP3A5*1/*3及CYP3A5*3/*3,CYP3A5*3/*3的TAC dnC0與dnC0/DW是CYP3A5*1/*1的2.2至2.7倍。其他顯著臨床因素跟一開始的臨床因素分析一樣,但納入基因之後整體的解釋力有上升,從原本的20%至26%變為33%至37%。此外,TAC劑量校正谷濃度隨著移植後的時間而增加, 結論: 在肝臟移植的病人,移植後六個月內,納入受贈者臨床與基因因素之迴歸分析顯示:顯著影響TAC dnC0或dnC0/DW的臨床因素有TAC的劑型(Prograf ®或Advagraf ®)、屍體或活體器官移植、PPI之使用、Hb、Hct、BUN、AST、bilirubin以及感染。基因型的部分,受贈者的CYP3A5基因變異在肝臟移植後的3個評估點皆會顯著影響TAC的dnC0與dnC0/DW。由當上述因子有顯著改變時,需要密切監測病人的TAC血中濃度。 | zh_TW |
dc.description.abstract | Background:
The large interindividual and intraindividual variations of tacrolimus (TAC) dose requirement are often observed in liver transplant recipients. According to the literature, many factors affected the pharmacokinetics (PK) of TAC. However, there was no study on the clinical and genetic factors analysis in liver transplant patients Taiwan. This study investigates clinical and genetic factors that significantly affected the pharmacokinetics of TAC in Taiwanese liver transplant recepients. Methods; The analysis was divided into two steps. Firstly, clinical factors of transplant recipients were analyzed. Then genetic polymorphisms of recepients were incorporated in the analyses. The cohort included liver transplant recipients who underwent transplants between January 1, 2008, and July 31, 2015, received TAC as immunosuppressant for at least 6 months, were tested specific genetic polymorphisms and transplanted at the age of 20 to 65 years. Exclusion criteria were retransplantation, multiorgan transplantation, non-Asian, and human immunodeficiency virus (HIV) positive patients. The concentrations of TAC were dose normalized, including dnC0 (dose normalized trough concentrations) and dnC0/DW (dosing weight and dose normalized trough concentrations). This study evaluates the dnC0 and dnC0/DW of TAC at three time points: the last C0 of steady state during hospitalization for transplant surgery, 3 months after transplant and 6 months after transplant. Covariates (clinical factors and genetic factors) with a p value of <0.20 in a univariate regression analysis were retained and entered into the multivariate regression analysis. Subsequently, multivariate regression analysis was performed with selected factors using a stepwise procedure. Other methods for statistical analysis include independent t-test, ANOVA (analysis of variance), Chi-squared test and Fisher's exact test. Result: A total of 123 liver transplant recipients were enrolled in the study. During hospitalization for transplantation, dosage form of TAC, direct bilirubin, living or deceased liver organ, PPI use and hematocrit (Hct) were significantly associated with TAC dnC0 or dnC0/DW. Three months after transplant, hemoglobin (Hb), aspartate aminotransferase (AST), dosage form of TAC, infection and blood urea nitrogen (BUN) were significantly associated with TAC dnC0 or dnC0/DW. Six months after transplant, AST, total bilirubin and Hb were significantly associated with TAC dnC0 or dnC0/DW. The coefficient of determination of individual factors were 314 %. Genetic polymorphisms of recepients were then incorporated in the analysis. After multiple regression with stepwise procedure, CYP3A5*3 was significantly associated with TAC dnC0 or dnC0/DW at all three time points and the coefficient of determination were 813%. TAC dnC0 and dnC0/DW of CYP3A5 non-expressers are 1.51.8 times of those in the CYP3A5 expressers. TAC dnC0 and dnC0/DW in patients with CYP3A5*3/*3 are 2.22.7 times of those with CYP3A5*1/*1. Clinical factors were the same as the initial analysis for clinical factors. But the coefficient of determination increased from 2026% to 3337%. Conclusion: Dosage form of TAC (Prograf ® or Advagraf ®), living or deceased liver organ, PPI use, Hb, Hct, BUN, AST, bilirubin and infection were significantly associated with TAC dnC0 or dnC0/DW in liver transplant recipients within 6 months after transplantation. CYP3A5*3 of liver transplant recipients was significantly associated with TAC dnC0 or dnC0/DW for all time points. TAC C0 should be closely monitored when there is a change in the factors mentioned above. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T02:40:00Z (GMT). No. of bitstreams: 1 ntu-106-R04451007-1.pdf: 2379959 bytes, checksum: d54d29a70f6e002e726d2c33197fdcab (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 論文口試委員會審定書 i
致謝 ii 縮寫表 iii 中英文對照表 v 中文摘要 ix 英文摘要 xi 目錄 xiv 圖目錄 xvii 表目錄 xviii 第一章、 前言 1 第二章、 文獻探討 3 2.1肝臟移植的免疫抑制劑使用情形 3 2.2 Tacrolimus的介紹 3 2.2.1 Tacrolimus的作用機制 4 2.2.2 Tacrolimus的毒性 5 2.2.3 Tacrolimus的劑型(Prograf®和Advagraf®) 5 2.3 Tacrolimus的藥動學特性 6 2.3.1 吸收 6 2.3.2 分布 7 2.3.3 代謝 7 2.3.4 排除 8 2.4 捐贈者對tacrolimus藥動學的影響 8 2.5基因多型性對tacrolimus藥動學的影響 8 2.5.1 CYP3A5 8 2.5.2 CYP3A4 9 2.5.4 POR*28 11 第三章、 研究目的及方法 13 3.1 研究目的 13 3.2 研究方法 13 3.2.1 研究架構 13 3.2.2 病人 14 3.2.3 臨床資訊收集流程 14 3.2.4 TAC穩定狀態之C0 15 3.2.5 給藥體重(dosing weight,DW)定義 15 3.2.6 TAC劑量校正C0(dose normalized C0,dnC0)定義 16 3.2.7 TAC抽血時間點 16 3.2.8 檢驗數據(laboratory data)採檢日期 17 3.2.9 併用藥品(combination drugs)定義 17 3.2.10 TAC血中濃度檢驗方法 18 3.2.11 Genotype方法 18 3.2.12 其它定義 19 3.2.13 統計分析 19 第四章、 研究結果 23 4.1 病人篩選流程 23 4.2 病人人口學資料 23 4.3免疫抑制劑與併用藥品 24 4.4 TAC劑量與血中濃度的變化 25 4.5 生化檢驗值的變化 25 4.6 單變項及多變項分析 26 4.7基因多型性與臨床因子分析 30 第五章、 討論 42 5.1 Prograf vs. Advagraf 42 5.2 Hemoglobin 43 5.3 AST 43 5.4感染 43 5.5氫離子幫浦阻斷劑 44 5.6 Bilirubin 45 5.7捐贈者的器官來源 46 5.8 BUN 46 5.9基因多型性 47 5.9.1 CYP3A5*3 47 5.9.2 CYP3A4*1G 48 CYP3A4*18B 48 第六章、 結論 51 參考文獻 52 圖表 65 | |
dc.language.iso | zh-TW | |
dc.title | ABCB1、CYP3A4、CYP3A5、POR基因多型性對肝臟移植病人tacrolimus血中濃度之影響 | zh_TW |
dc.title | The influence of ABCB1、CYP3A4、CYP3A5、POR genetic polymorphism on tacrolimus blood concentration in liver transplant patients | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 沈麗娟(ljshen@ntu.edu.tw) | |
dc.subject.keyword | tacrolimus,肝臟移植,藥品動態學,臨床因素,基因多型性,捐贈者, | zh_TW |
dc.subject.keyword | tacrolimus,liver transplantation,pharmacokinetics,clinical factors,genetic polymorphism,donor, | en |
dc.relation.page | 102 | |
dc.identifier.doi | 10.6342/NTU201703690 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-08-17 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf 目前未授權公開取用 | 2.32 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。